Shares in Takeda edged up modestly by 1.3%, reflecting a steady fiscal year 2025 performance that balanced ongoing LOE headwinds and pipeline progress, without clear market conviction on near-term growth catalysts.

• Core revenue was approximately JPY 4.5 trillion, partly pressured by loss of exclusivity in mature products.
• Core operating profit reached around JPY 1.17 trillion, supported by robust cost management and efficiency measures.
• Takeda delivered positive Phase III data for multiple late-stage assets, including oveporexton, rusfertide, and zasocitinib, setting the stage for potential regulatory approvals and launches in 2026.
• The pipeline was further strengthened with Phase III starts for elritercept and mezagitamab, and strategic oncology partnerships expanded future growth opportunities.
• Management emphasized disciplined commercial execution alongside innovation, signaling focus on upcoming launches amid a pivot to an evolved operating model to drive efficiency and sustainability.